; and (2) submit to the Congress and post on the public website of the Food and Drug Administration an updated report under subsection (c). 3. Evidence-based regulations, guidance, and policies to inform clinical opioid practices (a) In general To the maximum extent possible, the Commissioner of Food and Drugs shall ensure that regulations, guidance, and polices that are related to opioid prescribing practices and issued after the date of enactment of this Act are based on opioid prescribing practices that are evidence-based. (b) Statement To accompany guidelines and recommendations The Commissioner of Food and Drugs shall ensure that any opioid analgesic prescribing guidelines and other recommendations developed under this Act are accompanied by a clear statement that such guidelines or recommendations, as applicable— (1) are intended to help inform clinical decisionmaking by prescribers and patients; and (2) should not be used by other parties, including pharmacy benefit management companies, retail or community pharmacies, or public and private payors, for the purposes of restricting, limiting, delaying, or denying coverage for or access to a prescription issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. (c) Definition In this section, the term evidence-based means informed by a robust and systemic review of treatment efficacy and clinical evidence, including a review of the study and reports under section 2.